LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong early signals from consumer campaigns and a large market potential are positive, but the company's financials show a significant net loss and increased expenses. The Q&A highlights management's focus on consumer awareness and product efficacy, yet lacks clarity on some critical operational details. The absence of R&D spending could be concerning. Without clear guidance or a strong financial performance, the stock price is likely to remain stable over the next two weeks, resulting in a neutral sentiment.
Key Financial Performance
Net Revenue $1.9 million in Q1 2026, including $1.7 million from product sales. This represents a 19% increase compared to Q4 2025, driven by approximately 25,000 paid and filled prescriptions.
Prescriptions Approximately 25,000 paid and filled prescriptions in Q1 2026, a 19% increase compared to Q4 2025. This growth is attributed to new patient prescriptions and monthly refill units.
Gross to Net Discounts Blended gross to net discounts across distribution channels were less than 10%, resulting in approximately $67 in net revenue per monthly pack of VIZZ.
Cost of Sales $1.1 million in Q1 2026, primarily due to nonrecurring events such as an out-of-specification temperature excursion of inventory and a one-time charge for packaging supplies related to FDA-approved manufacturing process improvements.
SG&A Expenses $45 million in Q1 2026, or $40.7 million net of noncash stock-based compensation. This represents a 13% increase from Q4 2025, driven by planned direct-to-consumer (DTC) launch investments.
Net Loss $41.5 million in Q1 2026, resulting in a net loss per share of $1.32. This is consistent with the company's planned investments and operational expenses.
Cash Position $258.4 million in cash, cash equivalents, and marketable securities as of the end of Q1 2026. The net cash burn for the quarter was approximately $34 million, consistent with Q4 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VIZZ product performance: Approximately 25,000 paid and filled prescriptions in Q1, generating $1.9 million in net revenue, including $1.7 million in product sales. VIZZ is generating 30% more scripts per prescriber compared to VUITY at a similar stage of launch.
Patient adoption and persistence: Over 2/3 of e-pharmacy volume comes from 3-month prescriptions, indicating strong patient persistence. Patients are transitioning from trial to ongoing use effectively.
Manufacturing improvements: Transitioning to an FDA-approved, large-scale manufacturing process to improve product cost of goods and enhance vial format for better ease of use and comfort.
Global expansion: Strong momentum outside the U.S. with recent European and U.K. submissions and partnerships in China, Southeast Asia, Canada, the Middle East, and Latin America.
Physician engagement: Over 10,000 unique prescribers in Q1, with 60% prescribing VIZZ multiple times. High brand awareness among eye care professionals (ECPs).
Consumer strategy: Direct consumer campaigns driving engagement, with increased website traffic and strong signals of patient interest. Efforts to simplify the patient journey and improve conversion rates are underway.
Sales force expansion: Field organization expanded to target approximately 15,000 eye care professionals, increasing reach and frequency of engagement.
Adoption barriers and solutions: Identified barriers to adoption include lack of proactive physician-patient conversations and multi-step consumer journey. Actions include refining physician engagement strategies and introducing tools like QR-based resources for patients.
Contact lens patient focus: Targeting contact lens patients as a key demographic to drive adoption, addressing presbyopia-related challenges and improving patient retention.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
New Patient Adoption: The pace of new patient starts and routine ECP prescribing was more gradual than expected, requiring focused efforts to improve adoption.
Physician Engagement: Physicians are not proactively bringing up VIZZ in patient conversations, necessitating a behavioral shift to integrate the product into routine exams.
Patient Conversion: The multi-step process from awareness to prescription and purchase creates drop-off points, requiring simplification and clearer guidance for patients.
Manufacturing and Supply Chain: A temperature excursion of inventory during transit caused product loss, highlighting potential vulnerabilities in the supply chain.
Regulatory and Market Expansion: Global expansion efforts are ongoing, but regulatory approvals and market penetration in international regions remain challenges.
Financial Sustainability: High SG&A expenses, particularly in sales and marketing, and a significant net loss per share indicate financial pressures that need to be managed for long-term sustainability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
New Patient Adoption: The company is focused on accelerating new patient adoption through disciplined execution and targeted actions to address barriers to adoption. They aim to demonstrate measurable progress in new patient starts and routine ECP prescribing over the coming months and quarters.
Physician Engagement: LENZ is refining how VIZZ is introduced in the exam room to make it simpler and more natural for physicians to incorporate into their routine. They are focusing on contact lens patients as a key entry point and leveraging real-world feedback to improve physician adoption.
Consumer Strategy: The company is improving the patient journey from awareness to prescription and purchase by introducing tools like QR-based videos and onboarding resources. They are also testing additional media channels and refining messaging to enhance patient conversion and engagement.
Global Expansion: LENZ is advancing regulatory submissions in Europe and the U.K. and exploring partnerships in key markets such as Europe and Latin America. They are building on existing partnerships in China, Southeast Asia, Canada, and the Middle East to support global expansion.
Manufacturing Improvements: The company is transitioning to an FDA-approved, large-scale manufacturing process to improve product cost of goods, formulation specifications, and vial format. These changes aim to enhance the patient experience and support broader scale production.
Financial Outlook: LENZ expects to maintain a strong cash position and anticipates a reduction in quarterly cash burn after Q1 2026. They are targeting an allocation of approximately 80% of SG&A to sales and marketing to support growth initiatives.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are there encouraging signs beyond the current prescription trajectory for VIZZ, and can you identify specific practices prescribing VIZZ multiple times?
A:Management noted early indicators are strong, with high engagement in ads, increased website traffic, and positive consumer awareness. However, awareness is still early, and they are working on driving greater consumer awareness. Specific practices prescribing VIZZ multiple times were not directly addressed.
Q:Will specifics on refill dynamics be provided in the next earnings call?
A:Management confirmed that refill data will start to be shared in the second half of the year to allow patient behavior to mature over time.
Q:What is the sampling strategy and competitive dynamics with Tenpoint, Yuvezzi, and Qlosi?
A:Management emphasized that sampling is a core strategy, with VIZZ samples being more broadly distributed than competitors. They believe efficacy will determine the winner and highlighted VIZZ's unique MOA and long duration of efficacy. Competitors are also sampling, but not as broadly.
Q:What are the views on VIZZ's safety profile after 6 months on the market?
A:Management stated that VIZZ's safety profile is consistent with its label, with non-serious adverse events mostly transient. They reported 0 retinal detachments and 2 retinal tears, both in patients with pre-existing risk factors. They emphasized VIZZ's unique mechanism of action and lower perceived retinal risk compared to competitors.
Q:Why are prescribers not proactively discussing VIZZ with patients, and what efforts are being made to address this?
A:Management acknowledged that prescribers are not consistently bringing up VIZZ during standard exams. Efforts include sharpening messaging, providing digital resources like videos and QR codes, and focusing on contact lens wearers as a natural patient group.
Q:Is the assumption of average utilization of VIZZ for 5 months per year still valid?
A:Management confirmed that the assumption of 5 refills per year remains valid.
Q:How does the direct-to-physician sales model work, and what impact does it have on margins?
A:The model allows optometrists in certain states to buy VIZZ directly from the company and sell it to patients. Management stated that the economics are similar to other channels, with no meaningful difference in net economics to the company.
Q:What efforts are being made to expand beyond emerging presbyopes to a broader group?
A:Efforts include educating doctors on VIZZ's broad efficacy in moderate and advanced presbyopia, updating marketing materials, and using peer-to-peer statements to highlight successes in non-early presbyopes.
Q:What are the details of the network TV direct-to-consumer advertising pilot?
A:The pilot is being conducted in select key markets across the U.S., but it is too early to provide detailed results.
Q:Is the direct-to-physician sales initiative aimed at reducing prescription abandonment or incentivizing physicians?
A:Management stated that the initiative was driven by ECP demand and consumer convenience, not by prescription abandonment issues.
Q:Are there clauses in the direct-to-physician sales contracts to regulate pricing?
A:Doctors can set their own prices, but pricing pressures from other channels like e-pharmacy and retail help regulate the final price.
Q:What are the observations on switching from 1-month to 3-month refill dynamics?
A:Management observed that patients often start with a 1-pack and then switch to a 3-pack if they like the product. Approximately two-thirds of e-pharmacy volume now comes from 3-packs.
Q:Will R&D spending remain at zero for the foreseeable future?
A:Yes, management confirmed that R&D spending is expected to remain at zero, with the company focusing on commercial efforts.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing specific practices prescribing VIZZ multiple times and did not provide detailed results from the network TV advertising pilot.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ECPs VIZZ
QR
SGA cash
VIZZ exam
VIZZ patient
VIZZ practice
VIZZ product
VUITY
adoption physician
afternoon
approach
area
conversation
cost sale
distribution
example
expansion
feedback
month quarter
patient practice
physician VIZZ
prescriber base
prescribing behavior
prescribing habit
priority
product sale
scale
signal
stage launch
therapy
transition
understanding
unit
usage
use
value
volume
world
LENZ Transcript
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
Unknown5-11
The earnings call presents a mixed picture: strong early signals from consumer campaigns and a large market potential are positive, but the company's financials show a significant net loss and increased expenses. The Q&A highlights management's focus on consumer awareness and product efficacy, yet lacks clarity on some critical operational details. The absence of R&D spending could be concerning. Without clear guidance or a strong financial performance, the stock price is likely to remain stable over the next two weeks, resulting in a neutral sentiment.
LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call indicates a significant net loss increase, with a widening loss per share, which is a negative sign. Despite some positive signals in product adoption and marketing strategies, the lack of specific data on important metrics and the deferral of detailed refill metrics suggest uncertainties. The management's optimistic guidance on DTC efforts and sales force expansion is tempered by the potential delay in seeing results. Overall, the negative financial performance and uncertainties in execution outweigh the positive aspects, leading to a likely negative stock price reaction.
LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-4
LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call summary indicates a mix of positive and cautious elements. Strong early sales of VIZZ and positive initial feedback are promising, but management's reluctance to provide detailed guidance or conversion rates tempers enthusiasm. While the marketing strategy and spokesperson choice are well-received, the lack of specific prescription trends and financial guidance suggests uncertainty. The neutral sentiment reflects this balance of optimism and caution.
LENZ Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
